The Global bioburden testing market is expected to reach USD 907.4 million by 2024 from USD 452.6 million in 2016, at a CAGR of 9.1% in the forecast period 2017 to 2024. The new market report contains data for historic years 2014 & 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.
The market is segmented on the basis of test type, product type, technology, application, end-user, and geography.
On the basis of test type the market is segmented into aerobic, anaerobic, fungi and spore count.
Based on Product type the market is segmented into instruments and consumable. The instrument market segment is sub-segment into automated microbial identification systems, PCR (polymerase chain reaction), microscopes. The consumables market segment is sub segmented into kits, reagents and other consumables.
On the basis of technology microbial filter method, advanced colorimetric method and plate count method.
Based on ge0graphy the bioburden testing market is segmented into 5 geographical regions, North America, South America, Europe, Asia-Pacific and Middle East and Africa. The regions are further segmented into 15 major countries such as US, Mexico, Canada, India, China, Japan, Korea, Southeast Asia, and Brazil.The report includes company share data for different geographies including Global, North America, Europe and APAC.
Some of the major players operating in the bioburden testing market are Charles, Pacific Bio labs, Inc., Sigma-Aldrich Corporation, SGS S.A., WuXi PharmaTech Inc., Charles River Laboratories International Inc., Becton, Dickinson and Company, Merck & Co., Inc., North American Science Associates, Inc. (NAMSA), Nelson Laboratories, Inc., ATS Labs, Inc., Dynatec Labs, and among others.